Will We Have a Drug for Alzheimer's Disease by 2030? The View From Pharma

被引：7
|
作者：
Lovestone, Simon [1 ]
Manji, Husseini K. [2 ]
机构：
[1] Janssen Cilag, High Wycombe, Bucks, England
[2] Johnson & Johnson, Titusville, NJ USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷 / 01期
关键词：
TAU PATHOLOGY; HYPOTHESIS;
D O I：
10.1002/cpt.1685
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：79 / 81
页数：3
相关论文
共 50 条
  • [31] A Mitocentric View of Alzheimer’s Disease
    Hao Hu
    Chen-Chen Tan
    Lan Tan
    Jin-Tai Yu
    Molecular Neurobiology, 2017, 54 : 6046 - 6060
  • [32] Disease-Modifying Therapies in Alzheimer’s DiseaseHow Far Have We Come?
    Michael Hüll
    Mathias Berger
    Michael Heneka
    Drugs, 2006, 66 : 2075 - 2093
  • [33] How can we improve the drug development process in Alzheimer's disease?
    Brazell, C
    Corn, TH
    PROGRESS IN ALZHEIMER'S AND PARKINSON'S DISEASES, 1998, 49 : 833 - 839
  • [34] Alzheimer's disease What do we mean by Alzheimer's disease?
    Richards, Marcus
    Brayne, Carol
    BRITISH MEDICAL JOURNAL, 2010, 341 : 865 - 867
  • [35] Is infliximab the drug we have been waiting for in Crohn's disease? Commentary
    Bernstein, CN
    INFLAMMATORY BOWEL DISEASES, 2000, 6 (02) : 140 - 141
  • [36] Hypericin as a potential drug for treating Alzheimer's disease and type 2 diabetes with a view to drug repositioning
    Yuan, Xin
    Yan, Fei
    Gao, Li-Hui
    Ma, Qian-Hui
    Wang, Ju
    CNS NEUROSCIENCE & THERAPEUTICS, 2023, 29 (11) : 3307 - 3321
  • [37] Drug Development for Alzheimer's and Parkinson's Disease: Where Do We Go Now?
    Sequeira, Lisa
    Benfeito, Sofia
    Fernandes, Carlos
    Lima, Ines
    Peixoto, Joana
    Alves, Catarina
    Machado, Claudia Sofia
    Gaspar, Alexandra
    Borges, Fernanda
    Chavarria, Daniel
    PHARMACEUTICS, 2024, 16 (06)
  • [38] What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research
    Salkovic-Petrisic, Melita
    Knezovic, Ana
    Hoyer, Siegfried
    Riederer, Peter
    JOURNAL OF NEURAL TRANSMISSION, 2013, 120 (01) : 233 - 252
  • [39] What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer’s disease, about the therapeutic strategies in Alzheimer’s research
    Melita Salkovic-Petrisic
    Ana Knezovic
    Siegfried Hoyer
    Peter Riederer
    Journal of Neural Transmission, 2013, 120 : 233 - 252
  • [40] Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models?
    Marchetti, Cristina
    Marie, Helene
    REVIEWS IN THE NEUROSCIENCES, 2011, 22 (04) : 373 - 402
12345